Angela Loyse

Summary

Publications

  1. doi request reprint Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis
    Angela Loyse
    Infectious Diseases Unit, GF Jooste Hospital, Cape Town, South Africa
    Clin Infect Dis 54:121-8. 2012
  2. doi request reprint Neurological, visual, and MRI brain scan findings in 87 South African patients with HIV-associated cryptococcal meningoencephalitis
    A Loyse
    Department of Medicine, Edendale Hospital, Pietermaritzburg, South Africa Cryptococcal Meningitis Group, Research Centre for Infection and Immunity, Division of Clinical Sciences, St George s University of London, UK Electronic address
    J Infect 70:668-75. 2015
  3. doi request reprint Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries
    Angela Loyse
    Cryptococcal Meningitis Group, Research Centre for Infection and Immunity, Division of Clinical Sciences, St George s University of London, UK
    Lancet Infect Dis 13:629-37. 2013
  4. pmc Histopathology of the arachnoid granulations and brain in HIV-associated cryptococcal meningitis: correlation with cerebrospinal fluid pressure
    Angela Loyse
    Infectious Diseases Unit, GF Jooste Hospital, South Africa
    AIDS 24:405-10. 2010
  5. doi request reprint Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures
    Tihana Bicanic
    Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
    AIDS 23:701-6. 2009
  6. doi request reprint High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial
    Tihana Bicanic
    Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
    Clin Infect Dis 47:123-30. 2008
  7. pmc Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal
    Angela Loyse
    Cryptococcal Meningitis Group, Research Centre for Infection and Immunity, Division of Clinical Sciences, St George s Hospital Medical School, London, UK
    J Antimicrob Chemother 68:2435-44. 2013
  8. pmc Determinants of mortality in a combined cohort of 501 patients with HIV-associated Cryptococcal meningitis: implications for improving outcomes
    Joseph N Jarvis
    Research Centre for Infection and Immunity, Division of Clinical Sciences, St George s University of London, United Kingdom
    Clin Infect Dis 58:736-45. 2014
  9. pmc Early clinical and subclinical visual evoked potential and Humphrey's visual field defects in cryptococcal meningitis
    Anand Moodley
    Department of Neurology, Greys Hospital, Pietermaritzburg, South Africa
    PLoS ONE 7:e52895. 2012

Detail Information

Publications9

  1. doi request reprint Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis
    Angela Loyse
    Infectious Diseases Unit, GF Jooste Hospital, Cape Town, South Africa
    Clin Infect Dis 54:121-8. 2012
    ..Alternative, more widely available, and/or more effective antifungal combination treatment regimens are urgently needed...
  2. doi request reprint Neurological, visual, and MRI brain scan findings in 87 South African patients with HIV-associated cryptococcal meningoencephalitis
    A Loyse
    Department of Medicine, Edendale Hospital, Pietermaritzburg, South Africa Cryptococcal Meningitis Group, Research Centre for Infection and Immunity, Division of Clinical Sciences, St George s University of London, UK Electronic address
    J Infect 70:668-75. 2015
    ..Neuroradiological data is however limited to case reports and small case series from developed countries and/or immunocompetent patients...
  3. doi request reprint Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries
    Angela Loyse
    Cryptococcal Meningitis Group, Research Centre for Infection and Immunity, Division of Clinical Sciences, St George s University of London, UK
    Lancet Infect Dis 13:629-37. 2013
    ..We advocate ten steps that need to be taken to improve access to safe and effective antifungal therapy for cryptococcal meningitis...
  4. pmc Histopathology of the arachnoid granulations and brain in HIV-associated cryptococcal meningitis: correlation with cerebrospinal fluid pressure
    Angela Loyse
    Infectious Diseases Unit, GF Jooste Hospital, South Africa
    AIDS 24:405-10. 2010
    ..To investigate the histopathology of the arachnoid granulations in patients with HIV-associated cryptococcal meningitis and correlate the findings with clinical data, in particular cerebrospinal fluid (CSF) opening pressure...
  5. doi request reprint Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures
    Tihana Bicanic
    Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
    AIDS 23:701-6. 2009
    ....
  6. doi request reprint High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial
    Tihana Bicanic
    Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
    Clin Infect Dis 47:123-30. 2008
    ..A dosage range for AmB of 0.7-1 mg/kg per day is noted in current guidelines, but there are no data comparing 0.7 mg/kg per day with 1 mg/kg per day...
  7. pmc Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal
    Angela Loyse
    Cryptococcal Meningitis Group, Research Centre for Infection and Immunity, Division of Clinical Sciences, St George s Hospital Medical School, London, UK
    J Antimicrob Chemother 68:2435-44. 2013
    ..This article provides an up-to-date review of this evidence, and the current issues and challenges regarding increasing access to this key component of combination antifungal therapy for cryptococcosis. ..
  8. pmc Determinants of mortality in a combined cohort of 501 patients with HIV-associated Cryptococcal meningitis: implications for improving outcomes
    Joseph N Jarvis
    Research Centre for Infection and Immunity, Division of Clinical Sciences, St George s University of London, United Kingdom
    Clin Infect Dis 58:736-45. 2014
    ..Cryptococcal meningitis (CM) is a leading cause of death in individuals infected with human immunodeficiency virus (HIV). Identifying factors associated with mortality informs strategies to improve outcomes...
  9. pmc Early clinical and subclinical visual evoked potential and Humphrey's visual field defects in cryptococcal meningitis
    Anand Moodley
    Department of Neurology, Greys Hospital, Pietermaritzburg, South Africa
    PLoS ONE 7:e52895. 2012
    ..However, early optic nerve dysfunction can be detected by testing of VEP P100 latency, which may precede the onset of visual loss in CM...